Rallybio (NASDAQ:RLYB) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Rallybio (NASDAQ:RLYB) from a hold rating to a buy rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rallybio presently has a consensus rating of “Sell”.

Rallybio Trading Up 0.2%

Shares of NASDAQ RLYB opened at $16.99 on Friday. Rallybio has a 12 month low of $3.67 and a 12 month high of $17.57. The stock has a 50 day moving average of $16.09 and a 200-day moving average of $11.80. The company has a market capitalization of $90.23 million, a P/E ratio of -3.91 and a beta of -0.90.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Insider Activity

In other Rallybio news, major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the stock in a transaction dated Tuesday, May 19th. The shares were bought at an average cost of $13.98 per share, with a total value of $142,596.00. Following the completion of the acquisition, the insider owned 926,352 shares of the company’s stock, valued at $12,950,400.96. This trade represents a 1.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Rallybio

Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC lifted its position in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the period. Susquehanna International Group LLP raised its stake in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares in the last quarter. Geode Capital Management LLC raised its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares in the last quarter. Renaissance Technologies LLC lifted its position in Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares during the period. Finally, XTX Topco Ltd lifted its position in Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical?stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high?unmet?need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first?in?class or best?in?class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX?100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.